MDX-1203

N/A

Report date: 2024/02/05 13:55:40

Base Information

Drug NameMDX-1203
Drug Alias NameBMS-936561MDX-1203
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MED-A payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAlkylating agentsCD70 antigen inhibitorsDNA inhibitors
TargetsCD70 antigenDNA
Therapy Area/IndicationsCarcinoma, Renal CellLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol Myers Squibb Srlcompany
Active IndicationsN/A
Inactive IndicationsCarcinoma, Renal CellLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A